FIELD: medicine, pharmacy.
SUBSTANCE: method relates to medicine, namely to therapy, and concerns treatment of community-acquired pneumonia. To do this, starting from the third day of traditional treatment with antibiotics or antiviral drugs, single daily inhalations of surfactant-BL doses of 15-20 mg are performed during 7-10 days.
EFFECT: introduction of surfactant provides reduction in the duration of treatment of community-acquired pneumonia.
3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING CHRONIC OBSTRUCTIVE BRONCHITIS | 2015 |
|
RU2600822C1 |
| METHOD OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2015 |
|
RU2600833C1 |
| METHOD FOR TREATMENT OF ASTHMA | 2015 |
|
RU2611406C1 |
| METHOD FOR OBTAINING SURFACTANT FROM BOVINE LUNGS | 2018 |
|
RU2691648C1 |
| METHOD FOR COVID-19 PNEUMONIA TREATMENT | 2020 |
|
RU2745535C1 |
| METHOD OF TREATMENT OF PATIENTS WITH ACUTE BRONCHOPNEUMONIA COMPLICATED WITH ATELECTASIS | 1999 |
|
RU2149014C1 |
| METHOD FOR TREATING PERSISTENT PNEUMONIA PATIENTS WITH SURFACTANT-BL PREPARATION BEING APPLIED | 2006 |
|
RU2313378C1 |
| METHOD OF TREATING BRONCHOPULMONARY DISEASES | 2018 |
|
RU2695366C1 |
| METHOD OF DIAGNOSING VOLUME OF LUNG TISSUE AFFECTION IN CASE OF OUT-OF-HOSPITAL PNEUMONIA IN ADULTS BY DETERMINATION OF SERUM ALVEOMUCIN LEVEL | 2009 |
|
RU2407014C1 |
| METHOD FOR THE TREATMENT OF RESPIRATORY FAILURE AFTER ACUTE RESPIRATORY DISTRESS SYNDROME, REGARDLESS OF ETIOLOGY | 2022 |
|
RU2782103C1 |
